Evidence map›Paper›PMID 32107331›Full record

ArticleHaematologica2021

The Coup-TFII orphan nuclear receptor is an activator of the γ-globin gene.

Cristina Fugazza, Gloria Barbarani, Sudharshan Elangovan, Maria Giuseppina Marini, Serena Giolitto, Isaura Font-Monclus, Maria Franca Marongiu, Laura Manunza, John Strouboulis, Claudio Cantù and 6 more

Open access · goldAbstract read
In one paragraph

Article in Haematologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Role of Nuclear Receptors in Controlling Erythropoiesis.International journal of molecular sciences · 2022
    Review
  8. Article
  9. Physiological and Aberrant γ-Globin Transcription During Development.Frontiers in cell and developmental biology · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 4 countries.

Cristina FugazzaDipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, Milano, Italy.
Gloria BarbaraniDipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, Milano, Italy.
Sudharshan ElangovanDipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, Milano, Italy.
Maria Giuseppina MariniIstituto di Ricerca Genetica e Biomedica del Consiglio Nazionale delle Ricerche, Cagliari, Italy.
Serena GiolittoDipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, Milano, Italy.
Isaura Font-MonclusDipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, Milano, Italy.
Maria Franca MarongiuIstituto di Ricerca Genetica e Biomedica del Consiglio Nazionale delle Ricerche, Cagliari, Italy.
Laura ManunzaDip. di Sanità Pubblica, Medicina Clinica e Molecolare, Universita degli Studi di Cagliari.
John StrouboulisSchool of Cancer and Pharmaceutical Sciences, King's College London, United Kingdom.
Claudio CantùWallenberg Centre for Molecular Medicine, Linkoping University, Linköping, Sweden.
Fabio GasparriDepartment of Biology, Nerviano Medical Sciences S.r.l., Nerviano, Milano, Italy.
Silvia M L BarabinoDipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, Milano, Italy.
Yukio NakamuraRIKEN BioResource Research Center, Tsukuba, Ibaraki, Japan.
Sergio OttolenghiDipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, Milano, Italy.
Paolo MoiDip. di Sanità Pubblica, Medicina Clinica e Molecolare, Universita degli Studi di Cagliari.
Antonella Ellena RonchiDipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, Milano, Italy.
University of Milano-Bicocca · ITInstitute of Genetic and Biomedical Research · ITUniversity of Cagliari · ITKing's College London · GBLinköping University · SENerviano Medical Sciences · ITRIKEN BioResource Research Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The human fetal γ-globin gene is repressed in the adult stage through complex regulatory mechanisms involving transcription factors and epigenetic modifiers. Reversing γ-globin repression, or maintaining its expression by manipulating regulatory mechanisms, has become a major clinical goal in the treatment of β-hemoglobinopathies. Here, we identify the orphan nuclear receptor Coup-TFII (NR2F2/ARP-1) as an embryonic/fetal stage activator of γ-globin expression. We show that Coup-TFII is expressed in early erythropoiesis of yolk sac origin, together with embryonic/fetal globins. When overexpressed in adult cells (including peripheral blood cells from human healthy donors and β039 thalassemic patients) Coup-TFII activates the embryonic/fetal globins genes, overcoming the repression imposed by the adult erythroid environment. Conversely, the knock-out of Coup-TFII increases the β/γ+β globin ratio. Molecular analysis indicates that Coup-TFII binds in vivo to the β-locus and contributes to its conformation. Overall, our data identify Coup-TFII as a specific activator of the γ-globin gene.

Indexed as

gamma-GlobinsOrphan Nuclear ReceptorsCarrier ProteinsCOUP Transcription Factor IIHumansPromoter Regions, GeneticCarrier ProteinsCOUP Transcription Factor IIgamma-GlobinsNR2F2 protein, humanOrphan Nuclear Receptors

Identifiers

PMID32107331
PMCPMC7849756
OpenAlexW3008036942

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.